Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 80 of 84« First...102030...7879808182...Last »

Cantrixil Receives Orphan Drug Designation from FDA

SYDNEY, April 21, 2015 /PRNewswire/ — US-Australian drug discovery company, Novogen, today announced that its subsidiary joint venture company with Yale University, CanTx, Inc, has today received notification from the U.S. Food and Drug Administration (FDA) that its chemotherapy candidate drug, Cantrixil, has been granted Orphan Drug Designation for ovarian cancer. Orphan Drug Designation is an important […]

Read More »

Belgium, Netherlands plan joint purchase of rare disease drugs

(Reuters) – Belgium and the Netherlands will jointly negotiate the purchase of remedies for rare diseases with pharmaceutical groups, the Belgian health ministry said on Tuesday. The joint negotiations will focus on diseases which affect fewer than five in 100,000 people, so-called orphan diseases, for which treatments are often very expensive due to the limited […]

Read More »

Israel’s BrainStorm says stem cell drug benefits ALS patients

(Reuters) – Israel’s BrainStorm Cell Therapeutics said a mid-stage clinical trial of its adult stem cell treatment showed a “statistically significant” effect in patients with amyotrophic lateral sclerosis (ALS). According to the ALS Association, 5,600 people in the United States are diagnosed each year with the neurodegenerative disease, also known as Lou Gehrig’s Disease, which […]

Read More »

Pfizer Receives U.S. FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. announced today that XALKORI® (crizotinib) received Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the potential treatment of patients with ROS1-positive non-small cell lung cancer (NSCLC). Occurring in approximately one percent of NSCLC cases1, ROS1-positive NSCLC represents a particular molecular subgroup of NSCLC.2 XALKORI currently is approved […]

Read More »

AstraZeneca drug Lynparza shows promise in prostate cancer trial

(Reuters) – AstraZeneca’s recently approved ovarian cancer drug Lynparza, or olaparib, can also help men with prostate cancer, according to new clinical trial results on Tuesday. The news is the latest boost to the British company’s cancer drug pipeline, which formed a central plank of its defense against a $118 billion takeover attempt by Pfizer […]

Read More »

U.S. Census Bureau Daily Feature for April 21

WASHINGTON, April 21, 2015 /PRNewswire-USNewswire/ — Following is the daily “Profile America” feature from the U.S. Census Bureau: LIFESAVING MEDICINE Profile America — Tuesday, April 21st. One of world’s most important medicines — insulin —became available for general use this month in 1923, saving the lives of millions of people suffering from diabetes. Insulin is a hormone […]

Read More »

Eli Lilly’s Ixekizumab Succeeds in Late-Stage Study

INDIANAPOLIS, April 20, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a […]

Read More »

Merz Neurosciences to Present Key Clinical Data at the Annual Meeting of the American Academy of Neurology (AAN)

RALEIGH, N.C.–(BUSINESS WIRE)–Merz Neurosciences, a division of Merz North America (U.S. affiliate of the global Merz Pharma Group), announces that it will present top-line data from its Phase 3 PURE: Post-stroke Spasticity UppeR Limb Study to Investigate Efficacy and Safety of NT 201 clinical trial for incobotulinumtoxinA during the 67th Annual Meeting of the American […]

Read More »

New SU2C-American Cancer Society Lung Cancer Dream Team Announced

PHILADELPHIA, April 20, 2015 /PRNewswire-USNewswire/ — Stand Up To Cancer (SU2C) and the American Cancer Society (ACS) announced the formation of a $20 million Dream Team to attack the number one cancer killer in America, lung cancer, here today at the Annual Meeting of the American Association for Cancer Research (AACR), Scientific Partner to SU2C. ACS […]

Read More »

Curadev Wrangles a $555 Million Pact With Drug Giant Roche

Swiss drugmaker Roche (RHHBY) is doubling down on its immunotherapy oncology pipeline, on Monday announcing it will pay Indian company Curadev Pharma up to $555 million to develop and market its IDO1 and TDO inhibitors IDO1 (indoleamine-2, 3-dioxygenase-1) and TDO (tryptophan-2, 3-dioxygenase) are enzymes that mediate cancer-induced immune suppression, which tumor cells and a certain […]

Read More »

PPD Laboratories Opens Central Lab in Shanghai, China

Provides clients with broad range of standardized lab testing services and capabilities WILMINGTON, N.C. (April 20, 2015) – Pharmaceutical Product Development LLC (PPD) has opened a central laboratory in Shanghai, China, to deliver global scientific and technical laboratory expertise to meet growing client demand for these services in China. The new facility, which has been […]

Read More »

BioClinica Names Mukhtar Ahmed as eClinical President

-Technology and Industry Leader to Head eClinical Business Unit-    NEWTOWN, PENNSYLVANIA, April 20, 2015 – BioClinica®, Inc., a specialty clinical trials services and technology provider, today announced that Mukhtar Ahmed, a recognized business leader within the life sciences, healthcare and technology sectors, will join BioClinica on April 20th as President of its Global eClinical […]

Read More »

Lilly’s psoriatic arthritis drug succeeds in late-stage study

(Reuters) – Eli Lilly and Co said its experimental drug, ixekizumab, reduced the signs and symptoms of active psoriatic arthritis in patients more than a placebo did in a late-stage trial. Up to 30 percent of psoriasis patients develop psoriatic arthritis, an inflammatory form of arthritis that can cause swelling, stiffness and pain in and around […]

Read More »

Bristol-Myers immunotherapy combo promising in melanoma: study

(Reuters) – A combination of two Bristol-Myers Squibb drugs that help the immune system fight melanoma led to significantly greater tumor shrinkage than treatment with one of the medicines, according to a midstage study presented on Monday. The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared […]

Read More »

Epizyme Presents Preclinical Research Providing Deeper Understanding of Multiple Cancer Targets

PHILADELPHIA–(BUSINESS WIRE)–Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the presentation of data on two epigenetic targets in its pioneering therapeutic pipeline. These data were presented this week at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, Penn. Epizyme’s AACR 2015 posters […]

Read More »

Mindfulness therapy as good as medication for chronic depression – study

(Reuters) – Mindfulness-based cognitive therapy (MBCT) may be just as effective as anti-depressants in helping prevent people with chronic depression from relapsing, scientists said on Tuesday. Depression is one of the most common forms of mental illness, affecting more than 350 million people worldwide. It is ranked by the World Health Organization as the leading […]

Read More »

Immune System Drugs Melt Tumors In New Study, Leading A Cancer Revolution

The 49-year-old woman had had three melanoma growths removed from her skin, but now the disease was spreading further. A several-centimeter-sized growth under her left breast went deep into her chest wall. Some of the tissue in the tumor was dying because of lack of blood flow. Doctors at Memorial Sloan Kettering Cancer Center offered […]

Read More »

Tokai Pharmaceuticals Announces Preclinical Results from the University of Maryland Showing Galeterone and Analogs Inhibit Pancreatic Cancer Cell Growth

BOSTON–(BUSINESS WIRE)–Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a clinical-stage biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally-driven diseases, today announced that scientists in the laboratory of Vincent Njar, PhD, at the University of Maryland School of Medicine presented preclinical data showing that galeterone and novel analogs of galeterone inhibited growth, survival and […]

Read More »

Study shows new technology may improve management of leading causes of blindness

PORTLAND, Ore., April 20, 2015 /PRNewswire/ — Research published today in the Proceedings of the National Academy of Sciences (PNAS) demonstrates that technology invented by researchers at Oregon Health & Science University’s Casey Eye Institute can improve the clinical management of the leading causes of blindness. Optical coherence tomography (OCT) angiography could largely replace current dye-based […]

Read More »

Novartis solid tumor ‘CAR T cell’ still holds promise: researcher

(Reuters) – A new type of immuno-oncology treatment from Novartis AG proved safe in a tiny study of three types of solid tumors, but the trial included too few patients and used too small a dose of the experimental product to prove effectiveness, according to data presented at a cancer meeting on Sunday. The so-called […]

Read More »

Page 80 of 84« First...102030...7879808182...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation